316 related articles for article (PubMed ID: 21661014)
1. Researching bladder afferents-determining the effects of β(3) -adrenergic receptor agonists and botulinum toxin type-A.
Kanai A; Wyndaele JJ; Andersson KE; Fry C; Ikeda Y; Zabbarova I; De Wachter S
Neurourol Urodyn; 2011 Jun; 30(5):684-91. PubMed ID: 21661014
[TBL] [Abstract][Full Text] [Related]
2. Afferent mechanism in the urinary tract.
Kanai AJ
Handb Exp Pharmacol; 2011; (202):171-205. PubMed ID: 21290227
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
Kanai A; Zabbarova I; Oefelein M; Radziszewski P; Ikeda Y; Andersson KE
Neurourol Urodyn; 2012 Mar; 31(3):300-8. PubMed ID: 22275187
[TBL] [Abstract][Full Text] [Related]
4. Antimuscarinics and overactive bladder: other mechanism of action.
Yamaguchi O
Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
6. The afferent system and its role in lower urinary tract dysfunction.
Daly DM; Collins VM; Chapple CR; Grundy D
Curr Opin Urol; 2011 Jul; 21(4):268-74. PubMed ID: 21537194
[TBL] [Abstract][Full Text] [Related]
7. Detrusor myocyte activity and afferent signaling.
Andersson KE
Neurourol Urodyn; 2010; 29(1):97-106. PubMed ID: 20025035
[TBL] [Abstract][Full Text] [Related]
8. The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome.
Masunaga K; Chapple CR; McKay NG; Yoshida M; Sellers DJ
Neurourol Urodyn; 2010 Sep; 29(7):1320-5. PubMed ID: 20151470
[TBL] [Abstract][Full Text] [Related]
9. Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.
Cerruto MA; Asimakopoulos AD; Artibani W; Del Popolo G; La Martina M; Carone R; Finazzi-Agrò E
Urol Int; 2012; 89(1):1-8. PubMed ID: 22738896
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
Yokoyama O
Neurourol Urodyn; 2010; 29(1):107-11. PubMed ID: 20025014
[TBL] [Abstract][Full Text] [Related]
11. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of intravenous and intravesical application of vibegron, a β
Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
[TBL] [Abstract][Full Text] [Related]
13. What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017.
Malde S; Fry C; Schurch B; Marcelissen T; Averbeck M; Digesu A; Sahai A
Neurourol Urodyn; 2018 Jun; 37(S4):S108-S116. PubMed ID: 30133790
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β
Aizawa N; Fujimori Y; Nakanishi O; Hayashi T; Goi Y; Kobayashi JI; Fujita T
Eur J Pharmacol; 2021 May; 899():173995. PubMed ID: 33675781
[TBL] [Abstract][Full Text] [Related]
16. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Yamaguchi O
Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
[TBL] [Abstract][Full Text] [Related]
17. Developments in the pharmacotherapy of the overactive bladder.
Sellers DJ; McKay N
Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia.
Sawada N; Nomiya M; Hood B; Koslov D; Zarifpour M; Andersson KE
Eur Urol; 2013 Oct; 64(4):664-71. PubMed ID: 23838637
[TBL] [Abstract][Full Text] [Related]
19. Incontinence: How do β
Igawa Y; Aizawa N
Nat Rev Urol; 2017 Jun; 14(6):330-332. PubMed ID: 28322259
[No Abstract] [Full Text] [Related]
20. Control of bladder function by peripheral nerves: avenues for novel drug targets.
Fry CH; Ikeda Y; Harvey R; Wu C; Sui GP
Urology; 2004 Mar; 63(3 Suppl 1):24-31. PubMed ID: 15013649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
